RedHill Biopharma is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent protected, new formulations and combinations of existing drugs. RDHL’s current product pipeline includes treatments for: congestive heart failure, high blood pressure drug, chemotherapy and radiotherapy-induced nausea and vomiting prevention, acute migraine, Crohn’s disease, Multiple Sclerosis (MS), and Helicobacter pylori bacteria. For more information, visit the company’s Web site: http://www.redhillbio.com

Let us hear your thoughts below: